865
Participants
Start Date
May 3, 2022
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
contezolid acefosamil (IV)/contezolid (PO)
Contezolid acefosamil (IV)/contezolid (PO) administered for a total of 14 to 28 days (28 to 56 doses)
Linezolid (IV and PO)
Linezolid (IV and PO) administered for a total of 14 to 28 days (28 to 56 doses)
RECRUITING
ILD Research Center, Vista
RECRUITING
New Hope Research Development, Corona
RECRUITING
MHAT Sveti Nikolay Chudotvorets EOOD, Lom
RECRUITING
Multiprofile Hospital for Active Treatment - KANEV, Rousse
RECRUITING
Medical Institute Ministry of Interior Central Clinical Base, Sofia
RECRUITING
University Multidisciplinary Hospital for Active Treatment and Emergency Medicine 'N. I. Priogov´, Sofia
RECRUITING
South-Estonian Hospital Ltd., Võru
RECRUITING
LTD High Technology Hospital Med Center, Batumi
RECRUITING
JSC Vian - West Georgia Medical Center, Kutaisi
RECRUITING
GMV Care& Research - Maria Cecilia Hospital, Cotignola
RECRUITING
Daugavpils Regional Hospital, Daugavpils
RECRUITING
Instytut Medycyny Wsi im. W. Chodzki, Lublin
RECRUITING
PODEMA Sp. z o.o., Warsaw
RECRUITING
University Clinical Center Kragujevac, Kragujevac
Lead Sponsor
MicuRx
INDUSTRY